Back to today’s briefing

Story perspectives

$6.7 Billion Merger: Mallinckrodt and Endo Join Forces

3/13/2025

49 7

Summary

Story summary

Mallinckrodt and Endo are merging for $6.7 billion to form a diversified pharmaceutical company.
Endo shareholders will receive $80 million in cash and own 49.9% of the new entity.
Mallinckrodt shareholders will retain 50.1% ownership.
The merger aims to boost branded drug sales and tackle opioid litigation challenges.
The deal is set to close in late 2025, with projected revenue of $3.6 billion.

1 of 1

Story summary

Mallinckrodt and Endo are merging for $6.7 billion to form a diversified pharmaceutical company.
Endo shareholders will receive $80 million in cash and own 49.9% of the new entity.
Mallinckrodt shareholders will retain 50.1% ownership.
The merger aims to boost branded drug sales and tackle opioid litigation challenges.
The deal is set to close in late 2025, with projected revenue of $3.6 billion.